Tissue fillers derived from decellularized tissues are provided. The tissue fillers can include acellular tissue matrices that have reduced inflammatory responses when implanted in a body. Also provided are methods of making and therapeutic uses for the tissue fillers.

Embodiments of the present invention provide improved prosthetic devices. The prosthetic devices may be fabricated using environmental friendly, renewable and sustainable materials. Methods of manufacturing the devices are also provided. Additionally, the present invention provides an environmental friendly, renewable and sustainable substitute for carbon and/or fiberglass materials.

A biomimetic, polymeric composite biomaterial designed as a heart valve leaflet substitute that can be used for heart valve repair and/or to fabricate a new-generation of durable heart valve prosthesis.

A first alternative to a composition for preventing or retarding degradation of a functional coating on a medical device includes an antioxidant selected from gallic acid or a derivative thereof. A second alternative to a composition for preventing or retarding degradation of a functional coating on a medical device includes carboxymethyl cellulose or a derivative or salt thereof. The use of the compositions for preventing or retarding degradation of a functional coating on a medical device from reactive species generated during exposure of radiation, and a wetting agent comprising the compositions, are also provided. The wetting agent prevents or retards the hydrolytic degradation of the coating during the intended shelf-life of the wetted coated product.

The present invention, in which RPE cells are suspended in a medium pharmaceutically acceptable as an ocular irrigating/washing solution and containing a poloxamer, achieves improvement of the post-thawing survival rate of cryopreserved RPE cells, improvement of the photoreceptor cell protection effect by RPE cell transplanted immediately after thawing, and prevention of loss of RPE cells in various steps from thawing to transplantation.

The three-dimensional lattice structures disclosed herein have applications including use in medical implants, Some examples of the lattice structure are structural in that they can be used to provide structural support or mechanical spacing In some examples, the lattice can be configured as a scaffold to support bone or tissue growth Some examples can use a repeating modified rhombic dodecahedron or radial dodeca-rhombus unit cell. The lattice structures are also capable of providing a lattice structure with anisotropic properties to better suit the lattice for its intended purpose.

Pharmaceutical compositions, more specifically poloxamer copolymer-based compositions and hyaluronic acid-based compositions, containing amelogenin, are useful for promoting periodontal or orthopedic soft or hard tissue regeneration, wound closure, and skin regeneration and rejuvenation. The composition can contain a non-biodegradable thermosensitive pharmaceutically acceptable poloxamer copolymer in an amount of 18% to 30% by weight; amelogenin in an amount of 0.005% to 3% by weight; a disaccharide in an amount of 0.05% to 5% by weight; and an amino acid selected from alanine, glycine, isoleucine, leucine, proline, valine, and a mixture thereof in an amount of 0.05% to 5% by weight.

A bone graft composition comprising a viable, osteogenic cellular material combined with a viscous cryoprotectant that includes a penetrating cryoprotective agent and a non-penetrating cryoprotective agent. The viscosity of the cryoprotectant is such that the composition is malleable, cohesive and capable of being formed into desired shapes.

A first alternative to a composition for preventing or retarding degradation of a functional coating on a medical device comprising an antioxidant selected from gallic acid or a derivative thereof. A second alternative to a composition for preventing or retarding degradation of a functional coating on a medical device includes carboxymethyl cellulose or a derivative or salt thereof. The use of the compositions for preventing or retarding degradation of a functional coating on a medical device from reactive species generated during exposure of radiation, and a wetting agent comprising the compositions, are also provided. The wetting agent prevents or retards the hydrolytic degradation of the coating during the intended shelf-life of the wetted coated product.

The methods disclosed herein of generating three-dimensional lattice structures and reducing stress shielding have applications including use in medical implants. One method of generating a three-dimensional lattice structure can be used to generate a structure lattice and/or a lattice scaffold to support bone or tissue growth. One method of reducing stress shielding includes generating a structural lattice to provide sole mechanical spacing across an area for desired bone or tissue growth. Some examples can use a repeating modified rhombic dodecahedron or radial dodeca-rhombus unit cell. Some methods are also capable of providing a lattice structure with anisotropic properties to better suit the lattice for its intended purpose.